CDMO turnaround may be delayed
CDMO performance remained soft in Q2; management expects rebound in H2 but any delay in project ramp-ups or regulatory approvals could impact growth.
medium · management_commentaryAlivus Life Sciences Limited — Q2 FY26
Alivus Life Sciences reported a strong Q2 FY26 with revenue of ₹588 crore (up 16% YoY) and EBITDA margin of 33% (up 480 bps YoY), driven by a 39.7% growth in non-GPL API busines...
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
GPL recovery uncertain
GPL segment declined due to customer inventory rationalization; management expects recovery in H2 but could not quantify, leaving uncertainty.
medium · analyst_questionCapex delays may constrain future growth
Capex spend has been slower than planned; while management says it won't impact near-term growth, delays in capacity expansion could limit medium-term scalability.
low · analyst_questionRegulatory compliance incident at Gujarat plant
A flash fire led to a penalty from the Gujarat State Pollution Control Board; while management downplays it, repeated issues could affect operations.
low · analyst_question